HLA-B27 transgenic mice are susceptible to collagen-induced arthritis: Type II collagen as a potential target in human disease

Human Immunology

Volumn 61, Issue 2, 2000, Pages 140-147

  Lee, S ^a   Khare, Sanjay D ^a   Griffiths, M M ^b   Luthra, H S ^a   David, C S ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

Author keywords

HLA B27; Spondylarthropathies; Spontaneous arthritis; Transgenic mice; Type II collagen

Indexed keywords

COLLAGEN TYPE 2; HLA B27 ANTIGEN;

ARTHRITIS; CONFERENCE PAPER; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE PREDISPOSITION; FEMALE; GENETIC SUSCEPTIBILITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPONDYLOARTHROPATHY; T LYMPHOCYTE; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES; ANTIBODY SPECIFICITY; ARTHRITIS; AUTOANTIGENS; BETA 2-MICROGLOBULIN; COLLAGEN; DISEASE SUSCEPTIBILITY; FEMALE; HLA-B27 ANTIGEN; HUMANS; IMMUNIZATION; MALE; MICE; MICE, TRANSGENIC; NAIL DISEASES; SEX FACTORS; SPECIFIC PATHOGEN-FREE ORGANISMS;

EID: 0033959506     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0198-8859(99)00148-2     Document Type: Conference Paper

References (40)

1. Lau C.S., Burgos-Vargas R., Louthrenoo W., Mok M.Y., Wordsworth P., Zeng Q.Y. Features of spondyloarthritis around the world. Rheum Dis Clin N Am. 24:1998;753.
2. Khan M.A. An overview of clinical spectrum and heterogeneity of spondyloarthropathies. Rheum Dis Clin N Am. 18:1992;1.
3. Uksila J., Toivanen P. HLA-B27 and bacteria. Clin Rheumatol. 15:(Suppl 1):1996;44.
4. Hermann E., Yu D.T., Meyer zum Buschenfelde K.H., Fleischer B. HLA-B27-restricted CD8 T cells derived from synovial fluids of patients with reactive arthritis and ankylosing spondylitis. Lancet. 342:1993;646.
5. Ugrinovic S., Mertz A., Wu P., Braun J., Sieper J. A single nonamer from the Yersinia 60-kDa heat shock protein is the target of HLA-B 27-restricted CTL response in Yersinia-induced reactive arthritis. J Immunol. 159:1997;5715.
6. Scofield R.H., Warren W.L., Koelsch G., Harley J.B. A hypothesis for the HLA-B27 dysregulation in spondyloarthopathy contribution from enteric organisms, B27 structure, peptides bound by B27, and convergent evolution . Proc Natl Acad Sci USA. 90:1993;9330.
7. Scofield R.H., Kurien B., Gross T., Warren W.L., Harley J.B. HLA-B27 binding of peptide from its own sequence and similar peptides from bacteria implications for spondyloarthropathies . Lancet. 345:1995;1542.
8. Boisgerault F., Tieng V., Stolzenberg M.-C., Dulphy N., Khalil I., Tamouza R., Charron D., Toubert A. Differences in endogenous peptides presented by HLA-B*2705 and B*2703 allelic variants. J Clin Invest. 98:1996;2764.
9. Garcia F., Marina A., Albar J.P., Lopez de Castro J.A. HLA-B27 presents a peptide from a polymorphic region of its own molecule with homology to proteins from arthritogenic bacteria. Tissue Antigens. 49:1997;23.
10. Gao X.M., Wordsworth P., McMichael A. Collagen-specific cytotoxic T lymphocyte responses in patients with ankylosing spondylitis and reactive arthritis. Eur J Immunol. 24:1994;1665.
11. Tani Y., Sato H., Tanaka N., Mon K., Doida Y., Hukuda S. Serum IgAl and IgA2 subclass antibodies against collagens in patients with ankylosing spondylitis. Scand J Rheumatol. 26:1997;380.
12. Courtenay J.S., Daliman M.J., Dayan A.D., Martin A., Mosedale B. Immunization against heterologous type II collagen induces arthritis in mice. Nature. 283:1980;666.
13. Wooley P.H., Luthra H.S., Stuart J.M., David C.S. Type II collagen-induced arthritis in mice. I. Major histocompatibility complex (I region) linkage and antibody correlates. J Exp Med. 154:1981;688.
14. Mikecz K., Glant T.T., Baron M., Poole A.R. Isolation of proteoglycan-specific T lymphocytes from patients with ankylosing spondylitis. Cell Immunol. 112:1988;55.
15. Mikecz K., Glant T.T., Poole A.R. Immunity to cartilage proteoglycans in BALB/c mice with progressive polyarthritis and ankylosing spondylitis induced by injection of human cartilage proteoglycan. Arthritis Rheum. 30:1987;306.
16. Leroux J.-Y., Guerassimov A., Cartman A., Delaunay N., Webber C., Rosenberg L.C., Baneijee S., Poole A.R. Immunity to the G1 globular domain of the cartilage proteoglycan aggrecan can induce inflammatory erosive polyarthritis and spondylitis in BALB/c mice but immunity to G1 is inhibited by covalently bound keratan sulfate in vitro and in vivo. J Clin Invest. 97:1996;621.
17. Guerassimov A., Zhang Y., Banerjee 5, Cartman A., Webber C., Esdaile J., Fitzcharles M.-A., Poole A.R. Autoimmunity to cartilage link protein in patients with rheumatoid arthritis and ankylosing spondylitis. J Rheumatol. 25:1998;1480.
18. 2m an animal model of HLA-B27 associated human disorders . Cell. 63:1990;1099.
19. 2-microglobulin a model of human spondyloarthropathies . J Exp Med. 182:1995;1153.
20. Khare S.D., Hansen J., Luthra H.S., David C.S. HLA-B27 heavy chains contribute to spontaneousinflammatory disease in B27/human β2-microglobulin double transgenic mice with disrupted mouse β2m. J Clin Invest. 98:1996;2746-2755.
21. Weinrich S., Eulderink F., Capova J., Pla M., Gaede K., Heesemann J., vanAlphen L., Zurcher C., Hoebe-Hewryk B., Kievits F., Ivanyi P. HLA-B27 as a relative risk factor in ankylosing enthesopathy in transgenic mice. Hum Immunol. 42:1995;103.
22. Taurog J.D., Richardson J.A., Croft J.T., Simmons W.A., Zhou M., Femandez-Sueiro J.L., Balish E., Hammer R.E. The germfree state prevents development of gut and joint inflammatory disease in HLA-B27 transgenic rats. J Exp Med. 180:1994;2359.
23. Westman P., Partanen J., Leirisalo-Repo M., Koskimies S. Different DRB1*04 alleles predominate in the Finnish random population and in HLA-B 27-positive subpopulations. Tissue Antigens. 44:1994;327.
24. Tuokko J., Rnijonen H., Ilonen J., Anttila K., Nikkari 5, Mottonen T., Yli-Kerttula U., Toivanen A. Increase of HLA-DRBl*0408 and -DQB1*030l in HLA-B27 positive reactive arthritis. Ann Rheum Dis. 56:1997;37.
25. Khare S.D., Bull M.J., Hansen J., Luthra H.S., David C.S. Spontaneous disease in HLAB27 transgenic mice is independent of MHC class II molecules a direct role for B27 heavy chains and not B27 derived peptides . J Immunol. 160:1997;101.
26. Wooley P.H., Luthra H.S., Lafuse W.P., Huse A., Stuart J.M., David C.S. Type II collagen-induced arthritis in mice. III. Suppression of arthritis by using monoclonal and polyclonal anti-Ia antisera. J Immunol. 134:1985;2366.
27. Griffiths M.M., Nabozny G.H., Hanson J., Harper D.S., McCall S., Moder K.G., Cannon G.W., Luthra H.S., David C.S. Collagen-induced arthritis and TCRs in SWR and B10.Q mice expressing an Ek alpha transgene. J Immunol. 153:1994;2758.
28. Clague R.B., Shaw M.J., Holt P.J. Incidence and correlation between serum IgG and IgM antibodies to native type II collagen in patients with chronic inflammatory arthritis. Ann Rheum Dis. 40:1981;6.
29. Choi E.K., Gatenby P.A., McGill N.W., Bateman J.F., Cole W.G., York J.R. Autoantibodies to type II collagen occurrence in rheumatoid arthritis, other arthritides, autoimmune connective tissue diseases, and chronic inflammatory syndromes . Ann Rheum Dis. 47:1988;313.
30. Tani Y., Sato H., Tanaka N., Mon K., Doida Y., Hukuda S. Serum IgAl and IgA2 subclass antibodies against collagens in patients with ankylosing spondylitis. Scand J Rheumatol. 26:1997;380.
31. Charriere G., Hartmann D.J., Vignon E., Ronziere M.C., Herbage D., Ville G. Antibodies to types I, II, IX, and XI collagen in the serum of patients with rheumatic diseases Arthritis . Rheum. 31:1988;325.
32. Morgan K., Clague R.B., Collins I., Ayad 5, Phinn S.D., Holt P.J. Incidence of antibodies to native and denatured cartilage collagens (types II, IX, and XI) and to type I collagen in rheumatoid arthritis. Ann Rheum Dis. 46:1987;902.
33. Fielder M., Pirt S.J., Tarpey I., Wilson C., Cunningham P., Ettelaie C., Binder A., Bansal S., Ebringer A. Molecular mimicry and ankylosing spondylitis possible role of a novel sequence in pullulanase of Klebsiella pneumoniae . FEBS Lett. 369:1995;243.
34. Cremer M.A., Rosloniec E.F., Kang A.H. The cartilage collagens a review of their structure, organization, and role in the pathogenesis of experimental arthritis in animals and in human rheumatic disease . J Mol Med. 76:1998;275.
35. Gautam A.M., Liblau R., Chelvanayagam G., Steinman L., Boston T. A viral peptide with limited homology to a self peptide can induce clinical signs of experimental autoimmune-encephalomyelitis. J Immunol. 161:1998;60.
36. Wildner G., Thurau S.R. Cross-reactivity between an HLA-B27-derived peptide and a retinal autoantigen peptide a clue to major histocompatibility complex association with autoimmune disease . Eur J Immunol. 24:1994;2579.
37. Jardetzky T.S., Lane W.S., Robinson R.A., Madden D.R., Wiley D.C. Identification of self peptides bound to purified HLA-B27. Nature. 353:1991;326.
38. Khare S.D., Luthra H.S., David C.S. Unraveling the mystery of HLA-B27 association with human spondyloarthropathies using transgenic and knock out mice. Sem Immunol. 10:1988;15.
39. Jondal M., Schirmbeck R., Reimann J. MHC class I-restricted CTL responses to exogenous antigens. Immunity. 5:1996;295.
40. Browness P., Allen R.L., McMichael A.J. HLA-B27 can form heavy chain homodimers in vivo and in vitro, possible role of Cys 67 Arthritis . Rheum. 41:1998;S355.